CompletedPhase 1

Effect of Cinacalcet on Parathyroid Hormone Secretion in Children and Adolescents With Hypophosphatemic Rickets

United States8 participantsStarted 2005-06

Plain-language summary

This study will measure the effect of cinacalcet (Sensipar) on parathyroid hormone (PTH) secretion in children and adolescents with hypophosphatemic rickets (XLH). The investigators are seeking evidence that patients with XLH may benefit from treatment with cinacalcet by achieving better control of PTH secretion.

Who can participate

Age range5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Established patients with XLH * Age 5 years old and above * Normal serum calcium and creatinine concentrations Exclusion Criteria: * Patients with hypersensitivity to any component(s) of cinacalcet * Hypocalcaemia * Elevated serum creatinine

What they're measuring

Change of serum Parathyroid Hormone (PTH) with use of cinacalcet

Timeframe: Baseline, 30 minutes, and 4 hours post dose

Trial details

NCT IDNCT00195936

SponsorChildren's Mercy Hospital Kansas City

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2008-02

View on ClinicalTrials.gov More Hypophosphatemic Rickets, X-Linked Dominant trials